Rheumatology Network Newsletter

To view this email as a web page, click here.

Conference Report from the American Society for Bone and Mineral Research Annual Meeting

Osteoporosis Treatment Rises 118 Percent

The cost of treating osteoporosis in the United states has risen 118 percent over the last 19 years, shows an analysis presented this week at the American Society for Bone and Mineral Research annual meeting in Orlando.

Warfarin May Heighten Risk of Osteoporosis in Afib Patients

Patients with atrial fibrillation are commonly prescribed oral anticoagulants for stroke prevention, but in older patients at risk for osteoporosis, treatment with blood thinners may heighten osteoporosis risk, according to a study presented this week at the American Society for Bone and Mineral Research annual meeting in Orlando.

Alendronate Shows Promise as Alendronate Shows Promise as Maintenance Therapy for Osteoporosis

The bisphosphonate alendronate (Binosto and Fosamax) can effectively maintain the gains in bone mineral density achieved with a year-long course of denosumab treatment in 91 percent of 126 patients who participated in a randomized clinical trial presented this week at the American Society for Bone and Mineral Research annual meeting in Orlando.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.